The Ipamorelin literature, charted finding by finding.

Ipamorelin binds GHS-R1a — the G-protein coupled ghrelin receptor — on anterior pituitary somatotrophs via Gq/11-coupled phospholipase C signaling. PLC activation generates IP₃, which mobilizes intracellular calcium from the endoplasmic reticulum; rising cytosolic Ca²⁺ triggers GH vesicle exocytosis. Simultaneously, ipamorelin suppresses hypothalamic somatostatin tone — removing the inhibitory brake on GH pulsatility and amplifying pulse amplitude beyond what direct receptor stimulation alone would produce.^[1]

The downstream signal is physiological in architecture. GH exits somatotroph cells in a bounded pulse — peak concentration at 15–40 minutes post-injection SC, return to baseline within approximately three hours in rodent PK/PD models.^[2] IGF-1 rises secondarily as the liver responds to elevated GH. No direct stimulation of the GHRH receptor, the dopamine receptor, or the gonadotropin axis occurs at studied doses.^[1]

Ipamorelin does not require GHRH-R engagement to produce GH release. This is the mechanistic distinction from GHRH analogs (sermorelin, CJC-1295, tesamorelin): those peptides act on the GHRH receptor via Gαs/cAMP/PKA, a parallel pathway that increases the proportion of somatotrophs primed for secretion rather than triggering per-cell exocytosis directly. The two pathways are orthogonal, which is the basis for co-administration research.^[10][11]

The selectivity result is the most replicated finding in the ipamorelin literature. Raun et al. administered doses spanning 1–100 µg/kg IV to rats — a range exceeding 200-fold the GH-releasing ED₅₀ — and measured a full neuroendocrine panel.^[1] GH rose dose-dependently. ACTH did not. Cortisol did not. Prolactin did not. FSH, LH, and TSH showed no significant elevation at any studied dose.^[1] GHRP-2, GHRP-6, and hexarelin all produce measurable cortisol or prolactin elevation in equivalent models; ipamorelin does not. Raun et al. termed it "the first selective growth hormone secretagogue" in 1998. No subsequent publication has challenged that classification.

The hormonal selectivity has implications for research design. Studies measuring bone formation, body composition, or GI motility under ipamorelin can attribute observed effects to GH-axis changes without the confounding of elevated cortisol (catabolic) or prolactin (metabolic) acting simultaneously.^[1][4] The clean neuroendocrine background is an experimental advantage the earlier GHRPs do not provide.

Ipamorelin's selectivity profile also excludes direct testosterone stimulation. The LH/FSH axis — the gonadotropin pathway controlling sex hormone production — is not engaged by GHS-R1a agonism at studied doses.^[1] Testosterone levels are not expected to rise from GHS-R1a-specific peptide activity alone.

See Ipamorelin side effects in animal studies below for the adverse-event record that accompanies this selectivity profile.

Two bone studies anchor the ipamorelin literature. The first, Johansen et al. 1999, measured daily periosteal bone growth in adult female rats at three dose levels.^[3] Baseline periosteal bone growth rate was 42 µm/day. Ipamorelin raised it to 52 µm/day in a dose-dependent fashion. Total IGF-1, insulin-like growth factor binding proteins, and serum bone-metabolism markers were unchanged — indicating the elongation effect was mediated by local or pulsatile GH signaling at the growth plate, not by systemic IGF-1 elevation. Body weight gain increased significantly. The authors identified potential relevance for pediatric growth deficiency research.^[3]

The second study, Andersen et al. 2001, placed ipamorelin in a protection context.^[4] Adult female rats (8 months old) were exposed to glucocorticoids, which suppress bone formation. Concurrent ipamorelin at 100 µg/kg SC three times daily for three months counteracted that suppression: periosteal bone formation rate increased four-fold in the glucocorticoid + ipamorelin group versus glucocorticoid alone. Maximal tetanic muscle tension was also significantly restored.^[4] Glucocorticoid-induced osteopenia is a clinically recognized problem in medicine; ipamorelin's ability to counteract the suppression of bone formation in this rodent model is the result most frequently cited in the GHS body-composition and bone-protection literature.

The ghrelin receptor (GHS-R1a) is expressed not only on pituitary somatotrophs but on enteric cholinergic neurons throughout the GI tract — the mechanistic basis for studying ipamorelin in GI motility. Venkova et al. 2009 tested it in a rodent model of postoperative ileus.^[5] Single-dose ipamorelin at 1 mg/kg IV decreased time to first bowel movement. Repetitive dosing at 0.1 or 1 mg/kg IV significantly increased cumulative fecal pellet output, food intake, and body weight gain post-surgery. The motility mechanism was confirmed through ghrelin receptor agonism at GI motility neurons.^[5]

Greenwood-Van Meerveld et al. 2012 extended this to gastric emptying.^[6] In a rodent model of postoperative gastroparesis, ipamorelin reduced gastric content retention from approximately 78% (vehicle post-op) to approximately 52% — near the 44% observed in non-surgical controls. Isolated gastric tissue showed restored ACh-driven and electrically-stimulated contractility.^[6] The mechanistic chain — GHS-R1a agonism → cholinergic neuron activation → coordinated smooth muscle contraction — was confirmed in tissue preparations.

These preclinical findings were the basis for the Helsinn Therapeutics Phase 2 clinical trial (NCT00672074), which assessed ipamorelin IV for postoperative ileus management in humans.^[15] The trial completed; no NDA was submitted to the FDA.

Jiménez-Reina et al. 2002 studied the effects of 21-day subcutaneous ipamorelin treatment on the pituitary somatotroph population in young female rats.^[7] Two findings distinguished ipamorelin from GHRH. First, chronic ipamorelin significantly increased secretory granule volume density within somatotrophs (p < 0.05) — indicating that the cells accumulate more GH stores under sustained GHS-R1a stimulation. Second, in vitro culture experiments showed that ipamorelin, but not GHRH, increased GH content per somatotroph cell. GHRH, by contrast, increased granule volume density but not per-cell GH content.^[7]

This suggests that ipamorelin engages a pituitary regulatory loop that GHRH-class peptides do not reach directly — likely through the Gq/11 → PLC → Ca²⁺ cascade producing different transcriptional outcomes than the Gαs/cAMP/PKA pathway GHRH uses. Long-term pituitary plasticity under ipamorelin is the research implication; the practical significance in human models has not been characterized.

Body composition data in the ipamorelin literature is not uniformly favorable. Lall et al. 2001 administered GH secretagogues including ipamorelin chronically to both GH-deficient and GH-intact mice.^[8] The result: fat pad weights increased relative to body weight regardless of GH status. Serum leptin rose. Food consumption increased. Direct GH treatment decreased fat mass in GH-deficient mice; the GHS — which increases endogenous GH — increased fat mass through a GH-independent mechanism.^[8] The authors proposed that GHS-R1a agonism on adipose tissue or hypothalamic feeding circuits produces adiposity-stimulating effects that operate in parallel to, and can outweigh, the lipolytic effects of elevated GH.

The 2020 Sinha et al. review identified ipamorelin alongside sermorelin, GHRP-2, GHRP-6, and ibutamoren as compounds with evidence for lean mass gain and fat reduction in hypogonadal male models — while explicitly noting "a paucity of data examining the clinical effects" of ipamorelin in human populations.^[12] The lean mass accretion finding from bone studies (Johansen 1999 body weight gain^[3]) and the glucocorticoid-counteraction data (Andersen 2001^[4]) support a favorable body composition signal in specific research contexts; the Lall 2001 adiposity data is the counterweight requiring acknowledgment in any body composition discussion.

For Ipamorelin body composition findings, the evidence is model-dependent. GH-deficiency context, dose range, and co-agent status all modulate outcome direction.

CJC-1295 is a long-acting GHRH analog that binds the GHRH receptor via Gαs/cAMP/PKA signaling — a pathway mechanistically orthogonal to ipamorelin's GHS-R1a/Gq/Ca²⁺ route. The co-administration rationale derives from this orthogonality: CJC-1295 increases the proportion of somatotrophs primed for secretion (GHRH-axis effect); ipamorelin triggers acute GH exocytosis per primed cell (GHS-R1a effect). The two pathways recruit different intracellular signals to the same output — GH vesicle release — producing higher total GH exposure than either compound alone in studied models.

Teichman et al. 2006 established CJC-1295 pharmacology in healthy human adults (ages 21–61): a single subcutaneous dose of 30–60 µg/kg produced dose-dependent GH increases of 2–10-fold and IGF-1 elevations of 1.5–3-fold, persisting for 9–11 days.^[10] Estimated half-life was 5.8–8.1 days. No serious adverse events occurred. Ionescu and Frohman 2006 demonstrated that CJC-1295 preserves natural pulsatile GH secretion frequency and amplitude while raising basal GH levels 7.5-fold and mean GH levels 46%^[11] — confirming that GHRH-axis priming is compatible with superimposing an acute GHS-R1a pulse from ipamorelin without obliterating the underlying physiological pattern.

All framing for ipamorelin + CJC-1295 remains research-context only. No co-administration indication is FDA-approved. See Ipamorelin vs Sermorelin for the single-peptide GHRH-pathway comparison.

The adverse-event record for ipamorelin is sparse compared to earlier GHRPs, consistent with its selectivity profile. At the pharmacological level, the most documented concern is the GH-independent adiposity signal described by Lall et al. — fat mass increase via a non-GH mechanism at chronic doses in mouse models.^[8] Injection-site reactions and transient mild headache-analog signals are noted in rodent study observations; the selectivity panel (no cortisol, no prolactin) removes the acute stress-response adverse events that complicate GHRP-2 and hexarelin research.^[1]

Appetite effects are context-dependent. Single-dose administration produced no food intake change at 48 hours in the Venkova 2009 postoperative ileus model.^[5] Repetitive dosing in energy-depleted surgical animals did increase feeding — an observation consistent with GHS-R1a receptor biology but absent at the lower GH-stimulating doses used in other research contexts. Ipamorelin's selectivity profile reduces but does not eliminate the orexigenic signal associated with ghrelin receptor agonism.^[5]

Water retention is a class-level observation for GH-elevating interventions. At the physiological-range GH pulses produced by ipamorelin's dose ranges in rodent studies, edema signal appears minimal compared to direct recombinant GH administration, but fluid retention is a recognized research-model observation for GH-axis modulation generally.

Regulatory adverse signal (not pharmacological): WADA classifies ipamorelin as prohibited under S2 at all times. Anti-doping urinary detection methods for ipamorelin and its free-acid metabolites have been validated by Semenistaya et al. 2015.^[9] The FDA PCAC voted against 503A inclusion in October 2024^[16] — the compound is prohibited for compounding pharmacy use under current FDA policy.

Across the research literature, the principal findings are: (1) selective GH-axis stimulation without ACTH/cortisol/prolactin elevation at any studied dose — the founding result of the compound's characterization;^[1] (2) plasma half-life approximately 2 hours with GH pulse peak at 15–40 minutes and return to baseline within 3 hours;^[2] (3) dose-dependent longitudinal bone growth in rats, raising periosteal bone growth from 42 µm/day to 52 µm/day;^[3] (4) four-fold restoration of periosteal bone formation rate in glucocorticoid-suppressed models;^[4] (5) accelerated bowel recovery and near-normalization of gastric emptying in rodent postoperative models;^[5][6] (6) long-term pituitary somatotroph plasticity distinct from GHRH-class effects;^[7] (7) GH-independent adiposity increase at chronic doses in mouse models — the main body-composition caveat.^[8]

GH pulse onset is measured within 15–30 minutes of injection in rat models. Observable body-composition endpoints in longer studies are assessed over 4–12 week treatment windows. No large-scale longitudinal safety or efficacy data in humans exists; the Phase 2 trial for postoperative ileus (NCT00672074) is the most advanced human investigation to date.^[15]

Ipamorelin has not received FDA approval as an approved drug for any indication. The compound was studied in a Phase 2 randomized, quadruple-masked clinical trial (NCT00672074, Helsinn Therapeutics) for post-operative ileus; the trial completed, but no NDA was submitted.^[15] In October 2024, the FDA Pharmacy Compounding Advisory Committee voted against adding ipamorelin acetate to the 503A bulk drug substances list, leaving compounding pharmacy use prohibited under current FDA policy.^[16]

WADA classifies ipamorelin as a prohibited substance under S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics — banned at all times, in-competition and out-of-competition. No therapeutic use exemption pathway is available for ipamorelin under current WADA policy.^[9]